Search

AI-Based Prognostic Assay Validation for Early Breast Cancer

ClinicalTrials.gov registered NCT07541703, an observational study by Spotlight Medical and the Austrian Breast Colorectal Cancer Study Group (ABCSG) validating a locked AI-based prognostic assay in ER-positive/HER2-negative early breast cancer patients. The blinded retrospective study will use digitized H&E slides from ABCSG-8 with extended follow-up from ABCSG-16 to link assay outputs to clinical outcomes.